US5844061A - Polyphenol derivative compositions and perparation thereof - Google Patents
Polyphenol derivative compositions and perparation thereof Download PDFInfo
- Publication number
- US5844061A US5844061A US08/557,179 US55717995A US5844061A US 5844061 A US5844061 A US 5844061A US 55717995 A US55717995 A US 55717995A US 5844061 A US5844061 A US 5844061A
- Authority
- US
- United States
- Prior art keywords
- group
- acid
- compositions according
- derivative compositions
- polyphenol derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 27
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 24
- 239000000178 monomer Substances 0.000 claims abstract description 16
- 125000001424 substituent group Chemical group 0.000 claims abstract description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical group C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000004676 glycans Chemical class 0.000 claims abstract description 5
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 5
- 239000005017 polysaccharide Substances 0.000 claims abstract description 5
- 125000002252 acyl group Chemical group 0.000 claims abstract description 4
- 238000006467 substitution reaction Methods 0.000 claims abstract description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 3
- 239000005076 polymer ester Substances 0.000 claims abstract 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical group OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- -1 lauric Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 150000002205 flavan-3-ol derivatives Chemical class 0.000 claims description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- 238000003436 Schotten-Baumann reaction Methods 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical group 0.000 claims description 2
- 238000005063 solubilization Methods 0.000 claims description 2
- 230000007928 solubilization Effects 0.000 claims description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 claims description 2
- 125000005504 styryl group Chemical group 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- QAPAPLIQQTVEJZ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]ethanamine Chemical compound CCNCC1=CC=CC(F)=C1 QAPAPLIQQTVEJZ-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 abstract 1
- 101150035983 str1 gene Proteins 0.000 abstract 1
- 239000000047 product Substances 0.000 description 27
- 238000003756 stirring Methods 0.000 description 26
- 240000006365 Vitis vinifera Species 0.000 description 25
- 235000014787 Vitis vinifera Nutrition 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000004611 spectroscopical analysis Methods 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- 238000002329 infrared spectrum Methods 0.000 description 10
- 244000269722 Thea sinensis Species 0.000 description 9
- 235000009569 green tea Nutrition 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 7
- 235000011987 flavanols Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001236212 Pinus pinaster Species 0.000 description 5
- 235000005105 Pinus pinaster Nutrition 0.000 description 5
- 230000002225 anti-radical effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- 238000000622 liquid--liquid extraction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- YWEROEJPZVSWLT-UHFFFAOYSA-N (2-phenyl-3,4-dihydro-2H-chromen-3-yl) octadecanoate Chemical class C(CCCCCCCCCCCCCCCCC)(=O)OC1C(OC2=CC=CC=C2C1)C1=CC=CC=C1 YWEROEJPZVSWLT-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000002976 peresters Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GFZWTWNOLHLEJK-MHCRVGIVSA-N (2-phenyl-3,4-dihydro-2H-chromen-3-yl) (2E,4E)-hexa-2,4-dienoate Chemical class C(\C=C\C=C\C)(=O)OC1C(OC2=CC=CC=C2C1)C1=CC=CC=C1 GFZWTWNOLHLEJK-MHCRVGIVSA-N 0.000 description 1
- YDAZYPRHCPHDNZ-UHFFFAOYSA-N (2-phenyl-3,4-dihydro-2H-chromen-3-yl) hexanoate Chemical class C(CCCCC)(=O)OC1C(OC2=CC=CC=C2C1)C1=CC=CC=C1 YDAZYPRHCPHDNZ-UHFFFAOYSA-N 0.000 description 1
- GRTWTVFDPBKQNU-MQQKCMAXSA-N (2e,4e)-hexa-2,4-dienoyl chloride Chemical compound C\C=C\C=C\C(Cl)=O GRTWTVFDPBKQNU-MQQKCMAXSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- RUEOYQNDBAHZBS-UHFFFAOYSA-N 4-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]-4-oxobutanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCC(O)=O RUEOYQNDBAHZBS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- XRLCQRMNGQRGOC-MDZDMXLPSA-N ethyl (e)-3-[2,4-di(propan-2-yl)phenyl]prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(C(C)C)C=C1C(C)C XRLCQRMNGQRGOC-MDZDMXLPSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013572 fruit purees Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074047 glyceryl cocoate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- PKHMTIRCAFTBDS-UHFFFAOYSA-N hexanoyl hexanoate Chemical compound CCCCCC(=O)OC(=O)CCCCC PKHMTIRCAFTBDS-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004460 liquid liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005656 rearomatization reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940102548 stearalkonium hectorite Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UJJDEOLXODWCGK-UHFFFAOYSA-N tert-butyl carbonochloridate Chemical compound CC(C)(C)OC(Cl)=O UJJDEOLXODWCGK-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- BJQWBACJIAKDTJ-UHFFFAOYSA-N tetrabutylphosphanium Chemical compound CCCC[P+](CCCC)(CCCC)CCCC BJQWBACJIAKDTJ-UHFFFAOYSA-N 0.000 description 1
- IBWGNZVCJVLSHB-UHFFFAOYSA-M tetrabutylphosphanium;chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CCCC IBWGNZVCJVLSHB-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000500 vasculoprotective effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001643 venotonic effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/06—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing oxygen
- C09K15/08—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing oxygen containing a phenol or quinone moiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention relates to novel polyphenol derivative compositions and to their preparation.
- the invention relates more particularly to compositions containing polyhydroxylated derivatives of flavan and especially of 3-flavanol.
- the flavan ring system corresponds to the structure (x): ##STR2## the 3-flavanols possessing an --OH group in the 3-position.
- Flavanols polyhydroxylated on the benzene rings, may be obtained by extraction from various plant sources such as various species of pine, green tea or grape vine.
- the crude extracts isolated are formed of complex mixtures comprising monomers and polymers, more particularly oligomers ranging from diners and, most generally, up to decamers.
- the phenol groups present on the flavanol moieties impart to these OPCs anti-radical and antioxidizing properties which offer a potential advantage for numerous applications.
- Certain OPC extracts are used therapeutically as vascular protectors or in cosmetics.
- phenols are products which oxidize spontaneously on contact with atmospheric oxygen and/or in the presence of light, by involving a radical mechanism which may be represented by the following equation: ##STR3##
- radical derivatives of the following type are formed: ##STR4## which may then undergo ortho or para coupling to give condensation products of the following types: ##STR5##
- OPCs are water-soluble products, which poses a problem of compatibility with a good number of excipients used generally in the abovementioned applications, these excipients having, on the contrary, liposoluble properties.
- the aim of the invention is thus to provide highly stable polyphenol derivative compositions.
- the invention is also directed towards providing a process for the esterification of the phenol functions of these compositions, which process is easy to carry out and may be exploited on the industrial scale.
- the invention is also directed towards the exploitation of the anti-radical and anti-oxidizing properties of these compositions in various fields, in particular in therapy, in cosmetics and in dietetics.
- compositions of the invention are characterized in that they mainly contain oligomers or polymers whose monomer moieties correspond to the formula (I): ##STR6## in which A represents a group --OR, a hydrogen atom or a substituent R,
- R represents a group --COR 1 , R 1 being a saturated or unsaturated, linear or branched alkyl radical of at least two carbon atoms, or an aryl, aralkyl or aralkylene radical,
- substituent or substituents R which do not represent a group --COR 1 being a hydrogen atom, an alkyl group, an acyl group --CO--C 6 H 2 --(OH) 3 , a monosaccharide or a polysaccharide, and
- n 1 and n 2 which are identical to or different from each other, are numbers from 1 to 3, corresponding to the number of substitutions on a ring, and the diastereoisomers and the regioisomers of these moieties, the monomer moieties being connected by carbon--carbon bonds or by ether bridges between the rings which make up the flavan ring system.
- compositions thus esterified are of great stability. They may be stored for at least 2 years under normal storage conditions (temperature of 10° to 22° C., in light-protective packaging, hygrometry 40-50%).
- oligomers or the polymers of these esters correspond more especially to the formula II: ##STR7## in which A and R are as defined above,
- n 1 to n 6 which may be identical to or different from each other, are numbers from 1 to 3, representing the number of substituents on a benzene ring, and
- N is a number from 0 to 100, and the corresponding diastereoisomers and regioisomers.
- the bonds between the carbon atoms of the successive moieties are located between C-4 of one moiety and C-6 or C-8 of another moiety.
- Another family furthermore comprises at least two moieties connected by an oxygen bridge.
- Corresponding products correspond to the formula III: ##STR8## in which A, R, n 1 to n 6 and N are as defined above.
- the monomer moieties are more especially connected by an ether bridge between C-2 of one moiety and one of the carbons C 5 to C 8 of the next moiety.
- N is equal to 0 in the formula II or III above, the esters corresponding to dimers.
- N is a number from 1 to 10.
- N is greater than 10, in particular from 11 to 100.
- R1 advantageously represents a saturated or unsaturated fatty acid radical with, in this case, cis double bonds, this corresponding to the case which is the most common in natural products, or alternatively trans bonds, for products more particularly obtained synthetically or semi-synthetically.
- fatty acids examples are given below. According to the conventional nomenclature, the number of carbon atoms C, then the number of double bonds, and the position of these double bonds is shown for each of them. The names of the fatty acids are given for the most standard.
- the fatty acid radicals of C16 and greater are more particularly preferred with a view to cosmetic applications. These fatty acids are advantageously extracted from microalgae.
- R 1 represents an aryl group such as the phenyl radical.
- R 1 represents an aralkyl or aralkylene group, the alkyl or alkylene group being more particularly a C1 to C8 group, especially a C1 to C4 group.
- aralkyl and aralkylene groups which will be mentioned are the benzyl and styryl groups.
- compositions defined in the various arrangements above include monomeric esters, as a mixture with the oligomeric esters and/or the polymeric esters which constitute the main products.
- the invention is directed in particular towards flavanol derivative compositions.
- the substituent A represents a group --OR, R being as defined above.
- esters contain, where appropriate, an oxygen bridge between C-2 and one of the carbons C 5 to C 8 .
- esters of flavanol derivatives are obtained from OPCs extracted from plant sources.
- the plant materials most commonly used comprise various species of pine, grape vine and green tea.
- compositions defined above are obtained by reacting corresponding phenolic compositions having at least one free --OH group with an acylating agent which is capable of providing the radical --COR 1 , R 1 being as defined above, under conditions which allow the substitution of at least one free --OH group with an acyl radical --COR 1 .
- the acylating agent is advantageously chosen from acids R 1 COOH or derivatives of such acids, in particular acid chlorides R 1 COCl, anhydrides R 1 COOR 1 or esters R 1 COOR 2 , R 2 representing an aryl or C 1 -C 8 alkyl radical.
- the reaction is advantageously performed in the presence of an acid-activating agent.
- this agent consists of dicyclohexylcarbodiimide, but other agents imparting the same activating effect may be used, such as tert-butyl chloroformate (for formation of a mixed anhydride).
- the acylation reaction is carried out in the presence of a solvent which allows partial solubilization of the starting polyphenol compounds.
- Suitable solvents are chosen from halogenated derivatives such as dichloromethane, chloroform or 1,2-dichloroethane, or an amine such as pyridine.
- the reaction is preferably performed at room temperature.
- the reaction with the acid chloride or anhydride may be performed, as a variant, in aqueous alkaline medium, according to the Schotten-Baumann reaction.
- the polyphenol derivatives in aqueous phase at a pH of 7.5 to 12, in particular of 8 to 10 the acylating agent dissolved in an organic phase, and a phase transfer agent are placed together.
- the organic phase in which the acylating agent is dissolved is advantageously an organochlorine solvent such as chloroform or dichloromethane.
- phase transfer agents which will be mentioned are halides or hydroxides such as those of tetrabutylammonium or of tetrabutylphosphonium, hydrogen sulfates, for example tetrabutylammonium hydrogen sulfate, or alternatively benzyltriethylanmonium chloride.
- acylated derivatives obtained are separated from the reaction mixture and purified for the purposes of the applications envisaged. Suitable techniques comprise liquid-liquid extraction, chromatography and/or precipitation.
- the starting polyhydroxylated compositions are advantageously commercial products.
- these products are obtained by extraction from plants. They are preferably purified fractions.
- a conventional extraction process is derived from that described in Patent FR 1,427,100 (PV No. 998,508) of 14 Dec. 1964.
- the OPCs are extracted from the plant material by saturated aqueous NaCl solution. Liquid-liquid extraction with ethyl acetate is then carried out, and the OPCs are then precipitated by adding excess chloroform.
- the precipitate is taken up in ethyl acetate and subjected, if necessary, for the purposes of additional purification, to several cycles of reprecipitation with excess chloroform and uptake with ethyl acetate, the solvent being evaporated off at the end.
- these compositions are extracted from the plant material by water, followed by addition of NaCl.
- the impurities are precipitated and removed by filtration, followed by liquid-liquid extraction of the OPCs using ethyl acetate.
- the solvent is evaporated off and the residue taken up in water.
- the flavanol compositions are precipitated by adding excess chloroform, and are then filtered off and dried in the oven.
- the OPCs contain a sugar moiety as indicated above.
- This is a monosaccharide such as, for example, glucose or galactose, or polysaccharides formed from several of these monosaccharide units, which may be identical or different.
- These glycosylated derivatives are extracted from the plant material with water, an alcohol such as ethanol or methanol, or a water-acetone mixture (2/3). After washing with ethyl acetate, the extract is redissolved in aqueous solution. A liquid-liquid extraction with n-butanol is carried out, and the solvent is then removed by evaporation. The residue is subjected to countercurrent chromatographic purification or to chromatographic purification on Fractogel TSK HW40, Sephadex LH20, MCI CHP 20P gel or RP C18 silica gel.
- ester protecting groups On contact with esterases, which are present in the majority of biological tissues and media, at least some of the ester protecting groups are removed, regenerating the staring phenol compounds and the acids R 1 COOH. These compounds, in combination, exert their own activities, advantageously in a synergistic manner.
- compositions are thus particularly suitable for the development of pharmaceutical preparations.
- the pharmaceutical preparations of the invention contain an effective amount of at least one phenolic composition as defined above, in particular of a flavanol composition, in combination with an inert pharmaceutical vehicle.
- Advantageous pharmaceutical preparations contain these derivatives, alone or in combination with medicinal products which have a protective effect with respect to oxidation reactions.
- ⁇ -Carotene or vitamin E will be mentioned by way of example.
- these pharmaceutical preparations may be used in particular in the following therapeutic indications: circulatory disorders, venolymphatic insufficiency, skin capillary fragility, disorders involving retinal circulation, hemorrhoidal crisis, solar erythema or erythema associated with the action of radiation, for example in the case of radiotherapy.
- the pharmaceutical preparations of the invention may be administered orally.
- Use may be made in particular of tablets, pills, lozenges, gelatin capsules or drops. These preparations advantageously contain from 50 to 200 mg of OPC equivalent, preferably from 100 to 150 mg, per dosage unit.
- compositions of the invention may also be administered transdermally using patches, or alternatively in the form of nasal spray.
- compositions may be used for the prevention of mucitis, in the form of a gel applied directly to the mucous membranes liable to be irradiated.
- the dosage which may be used in man, for the pathologies considered corresponds to the following doses: phlebology and lymphology, 100 to 600 mg per day taken in two doses; ophthalmology, 100 to 400 mg per day; acute hemorrhoidal crisis: 200 mg to 1.2 g per day, radiotherapy: paste containing 1-5% of non-esterified polyphenol equivalent.
- compositions are also advantageously exploited for the development of cosmetic preparations.
- compositions are combined with vehicles which are suitable for external use. It will be noted that their liposoluble nature favors their incorporation into the pharmaceutical forms usually used in cosmetics.
- the preparations are in the form of a cream, a salve, an emulsion, a gel, liposomes or a lotion. They contain from 0.5 to 5% of active product.
- compositions of the invention may be used in dietetics.
- they provide better storage of foods.
- they generally constitute a supply of vitamin factor, in particular of vitamin P, with flavanol compositions. They are thus advantageously added to drinks, for example to fruit juices, tonic drinks and to dairy products and derivatives such as butter.
- They may also be used as they are in liquid form, or alternatively as granules or the like, as gels or in the form of a paste, for example incorporated into confectionery products such as fruit purees, confectionery sweets or chewing gums.
- compositions of the invention may be mixed with products of interest such as vitamins and/or trace elements and/or fish oils rich in unsaturated fatty acids, such as halibut oil, mackerel oil or salmon oil.
- products of interest such as vitamins and/or trace elements and/or fish oils rich in unsaturated fatty acids, such as halibut oil, mackerel oil or salmon oil.
- FIGS. 1 to 13 respectively represent:
- FIGS. 1 to 6 the UV, IR and one- and two-dimensional 13 C and 1 H NMR spectra of OPC perbutyrate from grape vine,
- FIGS. 7 and 8 the IR and 1 H NMR spectra of OPC perlaurate from grape vine
- FIG. 9 the IR spectrum of OPC perpalmitate from grape vine
- FIG. 10 the IR spectrum of OPC perlaurate from cluster pine
- FIGS. 11 and 12 the IR and 1 H NMR spectra of OPC perstearate from green tea
- FIG. 13 the IR spectrum of OPC peroleate from grape vine.
- Example 1 Preparation of OPC perbutyrate from grape vine.
- Example 3 Preparation of OPC perhexanoate from grape vine.
- Example 2 To 1 g of OPC from grape vine as mentioned in Example 1, dissolved in 5 ml of pyridine and kept stirring, are added dropwise 4.8 ml of hexanoyl chloride. The mixture is left stirring, at 60° C., in the absence of air (under a slight flow of nitrogen) and of light for 5 hours. After concentration under reduced pressure, the residue is treated as in Example 2. The product thus obtained is controlled by spectrometry.
- the organic phase is recovered and is washed with twice 100 ml of 0.1N sodium hydroxide solution, and then with twice 100 ml of distilled water.
- the organic phase is recovered and evaporated under reduced pressure. The product thus obtained is controlled by spectrometry.
- Example 5 Preparation of OPC persorbate from grape vine.
- Example 6 Preparation of OPC perlaurate from grape vine.
- Example 2 To 1 g of OPC from grape vine as mentioned in Example 1, dispersed in 50 ml of dichloromethane, are added, with stirring, 4.2 g of lauric acid followed by 4.3 g of dicyclohexylcarbodiimide (DCC). The mixture is left stirring, at room temperature, in the absence of air (under a slight flow of nitrogen) and of light for 2 hours. The reactive solution is treated as in Example 5. The product obtained is controlled by spectrometry (the IR and 1 H NMR spectra are represented in FIGS. 7 and 8).
- Example 7 Preparation of OPC perlaurate from cluster pine.
- Example 8 Preparation of OPC perpalmitate from grape vine.
- Example 2 50 g of OPC from grape vine as mentioned in Example 1 and 250 ml of pyridine are introduced into a one liter round-bottomed flask, under nitrogen. The mixture is stirred until dissolution is complete. 280 ml of palmitoyl chloride are added slowly (about 1 hour), using a dropping funnel. The reaction is exothermic. The mixture is left stirring for 3 hours. The mixture has then cooled to room temperature, and tends to set solid. 250 ml of chloroform are added and the stirring is continued at room temperature for 12 hours. The solvent is evaporated to dryness under reduced pressure and the residue is then taken up in 1 of chloroform.
- This solution is washed twice with 500 ml of 1N hydrochloric acid and then twice with 500 ml of distilled water. It is dried over 10 g of calcium sulfate, filtered and then evaporated to dryness under reduced pressure, without exceeding 40° C. The residue is taken up in 500 ml of acetone. The mixture is stirred for the purposes of dispersion (about 1 hour). It is filtered and then dried in a ventilated oven at about 25° C. for 12 hours. About 150 g of product are obtained, which product is controlled by spectrometry (the IR spectrum is represented in FIG. 9).
- Example 10 Preparation of OPC perstearate from green tea.
- Example 2 To 1 g of OPC from green tea, as mentioned in Example 2, are added 5 g of stearic acid dissolved in 80 ml of 1,2-dichloroethane. The mixture is stirred. 3.6 g of dicyclohexylcarbodiimide (DCC) are dissolved in 20 ml of 1,2-dichloroethane, and this solution is added to the previous. The mixture is left stirring at room temperature, in the absence of air (under a slight flow of nitrogen) and of light for 15 hours. The reactive solution is treated as in Example 5. The product thus obtained is controlled by spectrometry (the IR and 1 H NMR spectra are represented in FIGS. 11 and 12).
- DCC dicyclohexylcarbodiimide
- Example 11 Preparation of OPC perstearate from grape vine.
- Example 2 To 1 g of OPC from grape vine, as mentioned in Example 1, dissolved in 20 ml of distilled water, are added 100 ml of dichloromethane and the mixture is subjected to vigorous stirring (mechanical stirring at about 1000 revolutions per minute). 100 ml of a buffered aqueous solution of sodium phosphate and of sodium hydrogen phosphate (pH in the region of 11), 110 mg of benzyltriethylammonium chloride and then 6.0 ml of stearoyl chloride (in a single portion) are added. The mixture is left for 45 minutes under vigorous stirring. At the end of the reaction, the organic phase is recovered and is treated according to the procedure described in Example 4. The product thus obtained is controlled by spectrometry.
- Example 12 Variant for the preparation of OPC perstearate from grape vine.
- the chloroform phase is recovered, dried over anhydrous Na 2 SO 4 and filtered, and the solvent is then evaporated off under reduced pressure.
- the residue thus obtained is purified by preparative chromatography on activated silica with a chloroform-0.5% methanol solvent system. The product thus obtained is controlled by spectrometry.
- Example 13 Preparation of OPC peroleate from grape vine.
- Example 2 To 1 g of OPC from grape vine as mentioned in Example 1, dispersed in 50 ml of chloroform, are added, with stirring, 6.5 ml of oleic acid followed by 4.3 g of dicyclohexylcarbodiimide (DCC). The mixture is left stirring, at room temperature, in the absence of air (under a slight flow of nitrogen) and of light for 5 hours. The reactive solution is treated as in Example 10. The product obtained is controlled by spectrometry. The IR spectrum is represented in FIG. 13.
- Example 14 Preparation of flavanol stearates.
- OPC oligoprocyanidin
- the mixture is maintained at reflux for 24 hours with stirring.
- the dicyclohexylurea precipitate formed is removed by filtration.
- the organic phase is evaporated and the residue is taken up in CHCl 3 and subjected to a chromatographic purification.
- Example 15 Variant for the preparation of flavanol stearates.
- Example 15 The process is performed as in Example 15, but replacing the stearic anhydride and stearoyl chloride by the corresponding oleic acid derivative.
- Example 17 Preparation of flavanol sorbates.
- Example 19 Antisun cosmetic preparation.
- An antisun emulsion having cutaneous anti-ageing properties is prepared by mixing a sunscreen with an ester according to the invention and excipients for cream.
- composition of excipients is composition of excipients:
- Example 20 Anti-acne cosmetic preparation.
- An astringent and antiseptic O/W cream for greasy skin-types is prepared by mixing OPC persorbate according to Example 5, at a proportion of 1%, with an excipient for O/W cream.
- composition was used as excipient formulation:
- Example 21 Preparation of a venotonic and vasculoprotective medicinal product.
- Gelatin capsules are prepared from 270 mg of OPC perhexanoate from grape vine (corresponding to 100 mg of OPC) according to Example 3 and from excipients for a gastroresistant coating such as cellulose acetophthalate.
- Example 22 Preparation of gelatin capsules for use in dietetics.
- OPC perlaurate according to Example 6 is mixed with selenium and vitamin E;
- OPC perlaurate 105 mg (corresponding to 25 mg of OPC)
- Example 23 Oral gel which may be used in radio-therapy.
- composition is formulated:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
______________________________________ Neo Heliopan E 1000 ® 3% (isopropyl methoxycinnamate and ethyldiisopropyl cinnamate) OPC peroleate 3% accoding to Example 13 Excipients for W/O cream qs ______________________________________
______________________________________ Propylene glycol dicaprylate/dicarate sic! + 20.0% stearalkonium hectorite + propylene carbonate (Miglyol 840 gel B ®) Bis-diglyceryl caprylate/caprate/ 5.0% isostearate/hydroxystearate adipate (Softisan 649 ®) Isostearyl diglyceryl succinate 5.0% (Imwitor) 780 K ® sic! Liquid paraffin 8.0% Solid paraffin 3.0% Magnesium sulfate 2.0% Water qs 100% ______________________________________
______________________________________ Glyceryl cocoate + hydrogenated cocoa oil + 20.0% ceteareth-25 (Softisan 601 ® ) Glyceryl stearate SE (Imwitor 960 ® 8.0% flakes) Caprylic/capric/diglyceryl succinate 5.0% (Miglyol 829 ® ) Glyceryl ricineolate sic! 5.0% (Softisan 701 ® ) Glyceryl laurate (Imwitor 312 ® ) 5.0% Bis-diglyceryl caprylate/cparate/iso- 3.0% stearate/hydroxystearate adipate (Softisan 649 ® ) Silicone oil 344 fluid 1.0% Water qs 100% ______________________________________
______________________________________ 2% Carbopol ® 934 P gel 89.85 g Methyl para-hydroxybenzoate, sodium 0.13 g salt Propyl para-hydroxybenzoate, sodium 0.02 g salt Labrafil ® 5 g OPC perhexanoate from grape vine 5 g according to Example 3 (corresponding to 2 g of OPC from grape vine) ______________________________________
Claims (32)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9307140 | 1993-06-14 | ||
FR9307140A FR2706478B1 (en) | 1993-06-14 | 1993-06-14 | Compositions of phenolic derivatives, their preparation and their applications as antioxidants. |
PCT/FR1994/000712 WO1994029404A1 (en) | 1993-06-14 | 1994-06-14 | Polyphenol derivative compositions and preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US5844061A true US5844061A (en) | 1998-12-01 |
Family
ID=9448101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/557,179 Expired - Lifetime US5844061A (en) | 1993-06-14 | 1994-06-14 | Polyphenol derivative compositions and perparation thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US5844061A (en) |
EP (1) | EP0703954B1 (en) |
AU (1) | AU7076194A (en) |
CA (1) | CA2164863C (en) |
DE (1) | DE69429513T2 (en) |
ES (1) | ES2166374T3 (en) |
FR (1) | FR2706478B1 (en) |
PT (1) | PT703954E (en) |
WO (1) | WO1994029404A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391330B1 (en) | 2000-05-11 | 2002-05-21 | Michael A. Ross | Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa |
US20030108493A1 (en) * | 2000-02-11 | 2003-06-12 | Florence Henry | Extracts from residues left in the production of wine |
US20030132417A1 (en) * | 2002-01-11 | 2003-07-17 | Tokyo Seimitsu Co., Ltd. | Method and apparatus for preparing slurry for CMP apparatus |
US20030180405A1 (en) * | 1999-12-22 | 2003-09-25 | Gilles Pauly | Use of the residues from wine production |
US20040228816A1 (en) * | 1998-12-30 | 2004-11-18 | Carine Nizard | Cosmetic or dermatological composition containing an active agent which stimulates synthesis of the protein HSP 32 in the skin |
WO2005000831A1 (en) * | 2003-06-20 | 2005-01-06 | Cognis France, S.A.S. | ESTERS OF FLAVONOIDS WITH ω-SUBSTITUTED C6-C22 FATTY ACIDS |
WO2005048719A1 (en) * | 2003-11-17 | 2005-06-02 | Wisconsin Alumni Research Foundation | Polyphenol-containing stem and vine extracts and methods of use |
WO2006080328A1 (en) * | 2005-01-26 | 2006-08-03 | Suntory Limited | Esterified catechin, process for producing the same, food and drink or cosmetic containing the same |
US20080230744A1 (en) * | 2004-04-27 | 2008-09-25 | Tadahiro Hiramoto | Deoxidant Composition |
US20100266523A1 (en) * | 2007-11-15 | 2010-10-21 | Joseph Vercauteren | Compositions containing flavanoid polyphenol derivatives, and applications thereof in controlling diseases and ageing of living organisms |
JP2013528574A (en) * | 2010-04-12 | 2013-07-11 | ベルケム エス.ア. | Stabilized polyphenol derivatives, production method thereof, and use thereof |
US9000049B2 (en) | 2008-12-03 | 2015-04-07 | Laboratories Inneov SNC | Combination of lycopene, polyphenol, and vitamins for the care of keratin materials |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU742198B2 (en) * | 1996-04-02 | 2001-12-20 | Mars, Incorporated | Cocoa extract compounds and methods for making and using the same |
EP0862427A1 (en) * | 1996-09-18 | 1998-09-09 | Marigen S.A. | Ultramicroemulsions from spontaneously dispersible concentrates with antitumor, antiviral, virucide and antiparasitically active esters of bioflavonoid compounds |
JP3763075B2 (en) * | 1998-04-24 | 2006-04-05 | サンスター株式会社 | Food composition, oral composition and pharmaceutical composition for prevention or treatment of periodontal disease |
FR2778663B1 (en) | 1998-05-15 | 2001-05-18 | Coletica | NOVEL ESTERS OF FLAVONOIDS, THEIR USE IN COSMETICS, DERMOPHARMACY, PHARMACY AND AGRI-FOOD |
FR2781675B1 (en) * | 1998-07-31 | 2001-09-07 | Berkem Sa | BIOACTIVE PRODUCT CONTAINING SILICON AND BIOFLAVONOIDS, ITS PREPARATION METHODS AND ITS PHARMACEUTICAL, DIETETIC AND COSMETIC USES |
FR2792530B1 (en) * | 1999-04-21 | 2001-06-22 | Berkem Sa | PREPARATION OF A MEDICAMENT CONTAINING CATECHIC OR FLAVONILIC-TYPE POLYPHENOLIC COMPOUNDS OF PLANT ORIGIN, PARTICULARLY FOR THE TREATMENT OF GINGIVITIS |
FR2940615B1 (en) | 2008-12-30 | 2011-12-30 | Oreal | ASSOCIATION OF MONOSACCHARIDES WITH ANTIOXIDANT AGENTS AND ITS USE IN COSMETICS |
FR3017289B1 (en) * | 2014-02-07 | 2017-05-05 | Caudalie | HIGH-STRENGTH ANTIOXIDANT POWDER COMPOSITION BASED ON POLYOHENOL DERIVATIVES AND COSMETIC APPLICATION |
JP7118591B2 (en) | 2017-02-28 | 2022-08-16 | ロレアル | Compositions containing resorcinol or derivatives thereof |
JP7412898B2 (en) | 2019-04-26 | 2024-01-15 | ロレアル | Combination of unique particles and lipophilic antioxidants |
JP7612326B2 (en) | 2019-12-16 | 2025-01-14 | ロレアル | Stable compositions containing specific combinations of ingredients |
WO2024135424A1 (en) | 2022-12-20 | 2024-06-27 | L'oreal | Composition comprising hyaluronic acid-based polyion complex and hydrophilic or lipophilic antioxidant |
FR3145279A1 (en) | 2023-01-30 | 2024-08-02 | L'oreal | COMPOSITION COMPRISING A POLYIONIC COMPLEX BASED ON HYALURONIC ACID AND A LIPOPHILIC ANTIOXIDANT |
FR3148912A1 (en) | 2023-05-24 | 2024-11-29 | L'oreal | COMPOSITION COMPRISING CATIONIC AND ANIONIC POLYMERS |
FR3152226A3 (en) | 2023-08-25 | 2025-02-28 | L'oreal | ANHYDROUS COSMETIC COMPOSITION FOR A GENTLE AND LOW-GREASING APPLICATION |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1518003A1 (en) * | 1964-01-18 | 1969-01-30 | Merck Ag E | Process for the production of substituted flavan derivatives |
US4166861A (en) * | 1976-03-23 | 1979-09-04 | Inverni Della Beffa S.P.A. | Pharmacologically active polyphenolic substances |
US4255336A (en) * | 1977-11-25 | 1981-03-10 | Ciba-Geigy Corporation | Process for the preparation of O-substituted derivatives of (+)-cyanidan-3-01 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5695182A (en) * | 1980-12-18 | 1981-08-01 | Norin Suisansyo Chiyagiyou Shikenjo | Production of catechin |
JPS6320321A (en) * | 1986-07-14 | 1988-01-28 | Hitachi Ltd | epoxy resin composition |
JPH01233277A (en) * | 1988-03-15 | 1989-09-19 | Mitsui Norin Kk | Stabilization of catechins in aqueous solution |
JPH01268683A (en) * | 1988-04-20 | 1989-10-26 | Mitsui Norin Kk | Production of catechins having enhanced antioxidant power |
JP2857646B2 (en) * | 1990-11-26 | 1999-02-17 | キッコーマン株式会社 | Anti-mutagenic agent |
JP2902842B2 (en) * | 1991-12-13 | 1999-06-07 | 鐘紡株式会社 | Skin cosmetics |
JP3239191B2 (en) * | 1992-07-16 | 2001-12-17 | 鈴与株式会社 | Method for producing ingredients for whitening cosmetics |
-
1993
- 1993-06-14 FR FR9307140A patent/FR2706478B1/en not_active Expired - Lifetime
-
1994
- 1994-06-14 US US08/557,179 patent/US5844061A/en not_active Expired - Lifetime
- 1994-06-14 WO PCT/FR1994/000712 patent/WO1994029404A1/en active IP Right Grant
- 1994-06-14 ES ES94919709T patent/ES2166374T3/en not_active Expired - Lifetime
- 1994-06-14 EP EP94919709A patent/EP0703954B1/en not_active Expired - Lifetime
- 1994-06-14 CA CA002164863A patent/CA2164863C/en not_active Expired - Lifetime
- 1994-06-14 PT PT94919709T patent/PT703954E/en unknown
- 1994-06-14 DE DE69429513T patent/DE69429513T2/en not_active Expired - Lifetime
- 1994-06-14 AU AU70761/94A patent/AU7076194A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1518003A1 (en) * | 1964-01-18 | 1969-01-30 | Merck Ag E | Process for the production of substituted flavan derivatives |
US4166861A (en) * | 1976-03-23 | 1979-09-04 | Inverni Della Beffa S.P.A. | Pharmacologically active polyphenolic substances |
US4255336A (en) * | 1977-11-25 | 1981-03-10 | Ciba-Geigy Corporation | Process for the preparation of O-substituted derivatives of (+)-cyanidan-3-01 |
US4617296A (en) * | 1977-11-25 | 1986-10-14 | Ciba-Geigy Corporation | 3-O-acylated derivatives of (+)-cyanidan-3-ol |
Non-Patent Citations (16)
Title |
---|
Chemical Abstract Constituents of Phanus spinota 1992 Irizar et al. * |
Chemical Abstract Studies on the constituents of Ephedre 14. Validity of the oriental medicines 59. Structure of Mshusrrin C, a hypotensive principle of Ephedra roots. * |
Chemical Abstract, vol. 94, No. 11, Mar. 16, 1981, Columbus Ohio, Abstract No. 80196x, Dimeric Procyanidins from Juniperus Sabina, p. 379, Colonne R. * |
Chemical Abstract, vol. 96, No. 26, Jun. 28, 1982, Columbus, Ohio, Abstract No. 223079r, Otsuka Hiroshi, "Studies on Anti-inflammatory agents. VI. Anti-inflammatory Constituents of Cinnamomum Sisboldii Meissn.", p. 358. |
Chemical Abstract, vol. 96, No. 26, Jun. 28, 1982, Columbus, Ohio, Abstract No. 223079r, Otsuka Hiroshi, Studies on Anti inflammatory agents. VI. Anti inflammatory Constituents of Cinnamomum Sisboldii Meissn. , p. 358. * |
English Abstract of JP A 1 233 277 (Mitsui Norin KK), Sep. 19, 1989. * |
English Abstract of JP A 1 268 683 (Mitsui Norin KK), Oct. 26, 1989. * |
English Abstract of JP A 4 190 774 (Kikkoman Corp.) Jul. 9, 1992. * |
English Abstract of JP A 5 163 131 (Kanebo) Jun. 29, 1993. * |
English Abstract of JP A 56 095 182 (Noriinsho) Aug. 1, 1981. * |
English Abstract of JP A 6 040 883 (Suzuyo) Feb. 15, 1994. * |
English Abstract of JP A 63 020 321 (Hitachi), Jan. 28, 1988. * |
Eugen Muller ` Methoden der Organischen Chemie; Sauerstoffverbindungen III; (Houben-Weyl); 1952, Georg Thieme Verlog, Stuttgart, DE vierte Auflage, Band VIII, p. 559. |
Eugen Muller Methoden der Organischen Chemie; Sauerstoffverbindungen III; (Houben Weyl); 1952, Georg Thieme Verlog, Stuttgart, DE vierte Auflage, Band VIII, p. 559. * |
French Search Report, Mar. 1, 1994, in French Priority Application No. 93 07140. * |
PCT Search Report for PCT FR94/00712 (with English translation). * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040228816A1 (en) * | 1998-12-30 | 2004-11-18 | Carine Nizard | Cosmetic or dermatological composition containing an active agent which stimulates synthesis of the protein HSP 32 in the skin |
US20060078568A1 (en) * | 1999-12-22 | 2006-04-13 | Gilles Pauly | Use of the residues from wine production |
US20030180405A1 (en) * | 1999-12-22 | 2003-09-25 | Gilles Pauly | Use of the residues from wine production |
US20030108493A1 (en) * | 2000-02-11 | 2003-06-12 | Florence Henry | Extracts from residues left in the production of wine |
US6558689B2 (en) | 2000-05-11 | 2003-05-06 | Michael A. Ross | Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa |
US6391330B1 (en) | 2000-05-11 | 2002-05-21 | Michael A. Ross | Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa |
US20030132417A1 (en) * | 2002-01-11 | 2003-07-17 | Tokyo Seimitsu Co., Ltd. | Method and apparatus for preparing slurry for CMP apparatus |
WO2005000831A1 (en) * | 2003-06-20 | 2005-01-06 | Cognis France, S.A.S. | ESTERS OF FLAVONOIDS WITH ω-SUBSTITUTED C6-C22 FATTY ACIDS |
US20070184098A1 (en) * | 2003-06-20 | 2007-08-09 | Philippe Moussou | Esters of flavonoids with w-substituted c6-c22 fatty acids |
US20050129790A1 (en) * | 2003-11-17 | 2005-06-16 | Folts John D. | Polyphenol-containing stem and vine extracts and methods of use |
WO2005048719A1 (en) * | 2003-11-17 | 2005-06-02 | Wisconsin Alumni Research Foundation | Polyphenol-containing stem and vine extracts and methods of use |
US20080230744A1 (en) * | 2004-04-27 | 2008-09-25 | Tadahiro Hiramoto | Deoxidant Composition |
CN100457255C (en) * | 2004-04-27 | 2009-02-04 | 高砂香料工业株式会社 | Oxygen absorber composition |
WO2006080328A1 (en) * | 2005-01-26 | 2006-08-03 | Suntory Limited | Esterified catechin, process for producing the same, food and drink or cosmetic containing the same |
US20080058409A1 (en) * | 2005-01-26 | 2008-03-06 | Harukazu Fukami | Esterified Catechins, Processes for Producing the Same, and Foods and Beverages as well as Cosmetics Containing Such Esterified Catechins |
US20100266523A1 (en) * | 2007-11-15 | 2010-10-21 | Joseph Vercauteren | Compositions containing flavanoid polyphenol derivatives, and applications thereof in controlling diseases and ageing of living organisms |
US9000049B2 (en) | 2008-12-03 | 2015-04-07 | Laboratories Inneov SNC | Combination of lycopene, polyphenol, and vitamins for the care of keratin materials |
JP2013528574A (en) * | 2010-04-12 | 2013-07-11 | ベルケム エス.ア. | Stabilized polyphenol derivatives, production method thereof, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU7076194A (en) | 1995-01-03 |
EP0703954A1 (en) | 1996-04-03 |
FR2706478A1 (en) | 1994-12-23 |
CA2164863A1 (en) | 1994-12-22 |
ES2166374T3 (en) | 2002-04-16 |
FR2706478B1 (en) | 1995-09-08 |
PT703954E (en) | 2002-05-31 |
WO1994029404A1 (en) | 1994-12-22 |
CA2164863C (en) | 2006-05-23 |
DE69429513D1 (en) | 2002-01-31 |
DE69429513T2 (en) | 2002-08-08 |
EP0703954B1 (en) | 2001-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5844061A (en) | Polyphenol derivative compositions and perparation thereof | |
US9067908B2 (en) | Polyphenolic bioprecursors | |
EP0275224B1 (en) | Phospholipidic complexes of vitis vinifera extracts, process for their preparation and pharmaceutical and cosmetic compositions containing them | |
US6572882B1 (en) | Compositions based on resveratrol | |
JP3558922B2 (en) | Flavonoid compositions and their novel use in cosmetics | |
JP3241440B2 (en) | Cosmetics | |
ES2482115T3 (en) | Compositions of stylogenic polyphenolic derivatives and their applications to fight against the pathologies and aging of living organisms | |
EP0875514A1 (en) | Ascorbic acid derivative and vitamin C preparation containing the same | |
CA2796315A1 (en) | Stabilised polyphenol derivatives, process for their manufacture, and uses thereof | |
JP2007516937A (en) | Esters of flavonoids and ω-substituted C6-C22 fatty acids | |
KR20060008913A (en) | Stabilized derivatives of ascorbic acid | |
US5808119A (en) | Process for esterifying a polyphenolic oligomeric extract of plant origin, composition thus obtained and use thereof | |
WO2012086812A1 (en) | Glycoside compound | |
WO2005065637A1 (en) | Novel susnscreen reagents from hydroxy-substituted acylglycerides | |
JPH11217380A (en) | Ascorbyl sorbate, its production and its use | |
KR20020069202A (en) | Radioprotecting Agent | |
KR100714936B1 (en) | ?-acetylglucosamine Derivatives and Use Thereof | |
FR2835185A1 (en) | Rhubarb extract having antiradical, antioxidant and estrogenic action, used in medicaments, cosmetics or foods, contains synergistic combination of specific hydroxystilbene compounds | |
KR101451401B1 (en) | Conjugate of vitamin C with vitamin E and antioxidant comprising the same | |
JP4726505B2 (en) | External preparation for skin and skin whitening method | |
EP1296937A1 (en) | 3,4-dihydroxymandelic acid alkylamides and use thereof | |
DE60023585T2 (en) | Preparation of a medicament containing catechol- or flavonylic-like polyphenol compounds from plants, in particular for the treatment of gingivitis | |
JPH0580449B2 (en) | ||
KR102539794B1 (en) | Cosmetic composition for improving skin gloss or moisturizing skin comprising zwitterionic chitosan derivative | |
JP4959914B2 (en) | Topical skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OVI S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VERCAUTEREN, JOSEPH;WEBER, JEAN-FREDERIC;BISSON, JEAN-LOUIS;AND OTHERS;REEL/FRAME:007893/0198 Effective date: 19960116 Owner name: BERKAM, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OVI S.A.;REEL/FRAME:007847/0030 Effective date: 19960116 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |